SCHEMBL20340300

SCHEMBL20340300

C#Cc1ccc(NS(=O)(=O)c2c[nH]c3cc(S(C)(=O)=O)ccc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ATM Q13315 1/20 0.37
▸ TDO2 P48775 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ IDH1 O75874 2/20 0.36
▸ MAP2K7 O14733 1/20 0.36
▸ MAP2K4 P45985 1/20 0.36
▸ TP53 P04637 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ IMPDH2 P12268 1/20 0.35
▸ SGK1 O00141 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29561229 0.88 KDM1A (0.45) ALDH1A1LMNASMN1; SMN2MAP2K4TP53
SCHEMBL20354771 0.88 KDM1A (0.45) ALDH1A1LMNASMN1; SMN2MAP2K4TP53
SCHEMBL20339159 0.83 SGK1 (0.41) ALDH1A1LMNATP53MEN1KMT2A
SCHEMBL28316055 0.79 MEN1 (0.35) ALDH1A1SMN1; SMN2IDH1TP53HSD17B10
SCHEMBL29560216 0.75 KIF11 (0.39) ALDH1A1LMNASMN1; SMN2TDO2MAP2K7
SCHEMBL21545910 0.75 KIF11 (0.39) ALDH1A1LMNASMN1; SMN2TDO2MAP2K7
SCHEMBL29559968 0.74 TDO2 (0.43) ALDH1A1TDO2KMT2APOLB
SCHEMBL20355262 0.74 SGK1 (0.47) ALDH1A1LMNASMN1; SMN2IDH1MAP2K4
SCHEMBL20355384 0.74 TDO2 (0.43) ALDH1A1TDO2KMT2APOLB
SCHEMBL29560383 0.74 SGK1 (0.47) ALDH1A1LMNASMN1; SMN2IDH1MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110121499-B (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides 优时比制药有限公司 2022-12-20 — — CN claimed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 — — US claimed
EP-3562820-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB Pharma GmbH (DE) 2019-11-06 — — EP claimed
CN-110121499-A (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides 优时比制药有限公司 2019-08-13 — — CN claimed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 — — WO claimed
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2024-08-27 — — US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-04-28 — — US disclosed
US-20220048858-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-02-17 — — US disclosed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 — — US disclosed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 — — US disclosed
EP-3562820-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB Pharma GmbH (DE) 2019-11-06 — — EP disclosed
CN-110121499-A (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides 优时比制药有限公司 2019-08-13 — — CN disclosed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 — — WO disclosed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ALDH1A1 1065/4885LMNA 4619/4885SMN1; SMN2 840/4885
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 ALDH1A1 1065/4885LMNA 4619/4885SMN1; SMN2 840/4885
US-20220048858-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ALDH1A1 1065/4885LMNA 4619/4885SMN1; SMN2 840/4885
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ALDH1A1 1065/4885LMNA 4619/4885SMN1; SMN2 840/4885
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 ALDH1A1 1065/4885LMNA 4619/4885SMN1; SMN2 840/4885
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ALDH1A1 1065/4885LMNA 4619/4885SMN1; SMN2 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback